12 results about "Protein phosphorylation" patented technology

The invention discloses application of an NR1D1 protein phosphorylation site in preparation of cerebral hemorrhage treatment drugs, and belongs to the technical field of molecular biology. According to the invention, the specific phosphorylation site and phosphorylation modification level of the NR1D1 protein are determined for the first time, and the NR1D1 protein can be used as a key marker for evaluating the secondary nerve injury degree of the hemorrhagic cerebral apoplexy and developing treatment and / or alleviation of the hemorrhagic cerebral apoplexy; a specific antigen peptide and an antibody for accurately detecting the NR1D1 protein phosphorylation site are further constructed, and an efficient tool is provided for molecular evaluation of hemorrhagic stroke secondary nerve injury; meanwhile, polypeptide molecules capable of inhibiting NR1D1 protein phosphorylation are researched and developed, through the dual effects of specifically blocking the phosphorylation process and reducing protein degradation, necrosis of brain tissues around hematoma after hemorrhagic cerebral apoplexy is relieved, secondary dyskinesia is improved, and the effect of inhibiting NR1D1 protein phosphorylation is achieved. And a brand new scheme is provided for molecular evaluation and targeted intervention of hemorrhagic stroke secondary nerve injury.

The present application relates to a kind of FOXM1 protein phosphorylation modification interfering peptide and its application, belong to the field of biological medicine technology. Specifically, the present application is found in research, the transcriptional activity of FOXM1 protein depends on the condensate formed by its polymerization, destroying the polymerization of FOXM1 can effectively inhibit the occurrence and development of tumor, and the phosphorylation of the 376th amino acid of FOXM1 protein can also inhibit polymerization to some extent, thereby inhibiting the transcriptional activation of FOXM1 protein. Therefore, the present application designs an interfering peptide, and introduces phosphorylation modification in appropriate position, obtains a kind of phosphorylation modification interfering peptide FIP4 targeted to FOXM1 protein polymerization domain, the interfering peptide plays a significant role in inhibiting the transcriptional activation of FOXM1 protein in cell and animal in vivo, and can be used for treating tumor-related diseases.

This invention discloses the application of Panax notoginseng saponin Ft1 as a plant immune inducer in the control of bacterial plant diseases, belonging to the field of biopesticide technology. This invention is the first to discover that Panax notoginseng saponin Ft1 can effectively activate the plant immune system, promote the expression of the FRK1 immune marker gene, induce reactive oxygen species bursts and calcium ion influx, and activate MAPK protein phosphorylation, thereby enhancing plant resistance to bacterial diseases such as *Pseudomonas syringae*. Unlike other existing Panax notoginseng saponins that directly inhibit fungi as fungicides, Panax notoginseng saponin Ft1 works by activating the plant's own immunity and has no inhibitory effect on plant growth at effective concentrations. It is highly efficient, safe, and environmentally friendly, and can be used as a novel biopesticide for the control of bacterial plant diseases.

The application discloses a method for simultaneously identifying cell subgroups and related factor phosphorylation levels. The method simplifies the protein phosphorylation flow cytometry staining step without affecting the staining effect, can simultaneously detect 17 stained cells, and simultaneously saves cost and is more efficient. The method provided by the application can provide more accurate distinguishing ability, can obtain more information from a small cell sample, can detect abnormal cells at a low level, increases laboratory efficiency, is especially suitable for the research of the immune system, and has a wide prospect.

The invention discloses a targeted coupled small molecule and a preparation method, a pharmaceutical composition and application thereof. The designed compound can specifically inhibit FGFR in a targeted manner, has anti-proliferative activity to various tumor cells, has low toxicity to normal cells, and can play an anti-tumor effect through various mechanisms such as protein phosphorylation inhibition and DNA damage induction. Meanwhile, the compound also shows the characteristics of high efficiency and low toxicity in vivo, and has a good patent medicine prospect.

The invention belongs to the technical field of stem cell differentiation regulation and control, and particularly relates to a method for inducing SDSCs to be differentiated into PGCLCs by BMP4 through a TGF-beta signal channel and application. The invention provides a method for inducing SDSCs to differentiate into PGCLCs by BMP4 through a TGF-beta signal channel, which comprises the following steps: placing SDSCs in a culture environment containing BMP4, and activating the TGF-beta signal channel to differentiate the SDSCs into the PGCLCs, wherein the activation of the TGF-beta signal channel is shown as the up-regulation of the protein phosphorylation level of SMAD1 / 5 / 8. The invention discloses a complete mechanism that BMP4 induces differentiation through a TGF-beta signal channel, and the BMP4 activates SMAD1 / 5 / 8 phosphorylation and up-regulates ID family transcription factor expression so as to regulate reproductive structure development and chromatin remodeling related target genes, thereby providing a theoretical basis for directional differentiation of stem cells.

The invention discloses application of a CCNB1 phosphorylation inhibition tool in preparation of a medicine for preventing and / or treating triple negative breast cancer, and particularly relates to application of a CCNB1 protein S128 site phosphorylation inhibitor in preparation of a medicine for preventing and / or treating triple negative breast cancer. The phosphorylation inhibitor refers to a tool or means used in the process of blocking or weakening protein phosphorylation, particularly a gene editing system, and the 128 serine Ser coded by a CCNB1 gene is mutated into alanine Ala which is recorded as S128A in a target cell. Compared with a traditional small molecule drug, the gene editing tool accurately intervenes phosphorylation modification at the gene level, has the advantages of being clear in mechanism, high in targeting performance, high in safety and the like, is suitable for basic research and potential clinical transformation of TNBC targeted therapy, and has a good application prospect.

The invention discloses a D53 protein phosphorylation modification site deletion mutant and application of the D53 protein phosphorylation modification site deletion mutant in regulation and control of plant types. Serine at the 589th site of the protein D53 is mutated into aspartic acid, amino acid sequences at other positions are not changed, the protein D53S589D is obtained, the serine at the 589th site of the protein D53 is mutated into aspartic acid, and the phosphorylation state of the serine at the 589th site of the protein D53 is simulated. Experiments prove that the protein D53 is mutated into the protein D53S589D in a rice genome, that is, the tillering number of rice can be increased by improving the phosphorylation level and / or activity of the 589th serine of the protein D53. The method provided by the invention can directionally improve the tillering character of rice, and has important application value.

The application relates to the technical field of data processing, and discloses a PRAK signal pathway analysis method and system. The method comprises the following steps: collecting circRNA expression profiles, miRNA regulation data and PRAK pathway protein phosphorylation data by high-throughput sequencing technology to form a comprehensive data set, mining molecular interaction relationships to construct a pathway connection matrix containing three regulation axes of P38-PRAK-HSP27, VEGFA-PRAK and PRAK-GTPBP4-RhoA, predicting the PRAK pathway activation strength value by using a graph neural network algorithm, extracting the response characteristic markers of a chemotherapy-resistant type, an apoptosis-sensitive type and a proliferation regulation type, and matching an optimal PRAK pathway intervention target point combination. The application solves the technical problem that the existing PRAK signal pathway analysis method cannot intelligently process multi-omics data and accurately predict the pathway activity state.

The invention relates to the technical field of data processing, and discloses a PRAK signal path analysis method and system. The method comprises the steps that a circRNA expression profile, miRNA regulation and control data and PRAK pathway protein phosphorylation data are collected through a high-throughput sequencing technology to form a comprehensive data set, the molecular interaction relation is mined to construct a pathway connection matrix containing three regulation and control axes of P38-PRAK-HSP27, VEGFA-PRAK and PRAK-GTPBP4-RhoA, the PRAK pathway activation intensity value is predicted through a graph neural network algorithm, and the PRAK pathway activation intensity value is calculated. Chemotherapy drug resistance type, apoptosis sensitive type and proliferation regulation type response feature identifiers are extracted, and the optimal PRAK pathway intervention target combination is matched. The technical problem that an existing PRAK signal channel analysis method cannot intelligently process multi-omics data and cannot accurately predict the active state of the channel is solved.

The present disclosure provides for high affinity variants of SH2 domains, methods of manufacturing such compositions, their use in screening, and in methods of their administration. The compositions and methods provided herein can be used for targeting protein phosphorylation of tyrosine residues as a means for identifying markers of pathology for therapeutic interventions.

The invention relates to the field of biological information, and discloses a protein phosphorylation site function evaluation method based on a kinetic model in combination with an artificial intelligence algorithm. Comprising the following steps: S1, acquiring intracellular omics data of cells under N conditions; s2, taking the omics data under each condition as a reference one by one, substituting the data in the S1 into a kinetic model, and estimating model parameters by introducing a Bayesian algorithm; meanwhile, whether a certain protein phosphorylation site has functions or not under the current reference condition is evaluated through likelihood ratio test; and S3, repeating the step S2 for N times until each condition serves as a reference, summarizing the results of a certain protein phosphorylation site under N iterations, and estimating the probability that the potential protein phosphorylation site has a regulation function under N conditions by adopting a maximum likelihood estimation method. According to the method, the model parameter estimation capability of an artificial intelligence algorithm is fully utilized, protein abundance data are integrated, phosphorylation abundance data are also integrated, model solving is more accurate, and false positive occurrence is reduced.